CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis

Gastric cancer (GC) is the fifth leading cause of cancer death in Taiwan, although its incidence and mortality rate have been declining in the past five decades. Globally, GC is fourth most common among all types of cancer diagnoses, and is the second leading cause of cancer mortality [1], despite improvements in surgical techniques and development of new chemotherapeutic regimens. Annual deaths have reached 700,000 worldwide and 42% are reported in China alone [1]. Even after curative resection, 40% of patients with advanced gastric cancer die of recurrence [2]. The prognosis for patients after curative surgery remains poor due to the high recurrence rate. The overall 5-year survival rate for patients who undergo curative surgical resection for gastric carcinoma ranges from 47% to 60.4%, and the recurrence rate ranges from 15.4% to 37% [3].

Genetic susceptibility variants and molecular alterations related to environmental and lifestyle factors are known to contribute to development of GC, but even though many studies have investigated molecular markers for the disease, the true mechanisms of GC carcinogenesis remain obscure [3]. Recurrence mechanisms also lack definitive explanation [4]. Even though we know gastric carcinoma is prone to recur despite curative resection, no molecular biomarker is currently available to predict gastric carcinoma recurrence after resection. While clinical predictive factors, such as tumor staging, can predict recurrence of advanced gastric cancer and are well recognized as essential predictors of prognosis, is there any molecular-based biomarker that can serve as a useful predictor for recurrence of advanced gastric cancer after curative resection (R0 resection)?

Both CD44 and CD24 are known to contribute to cellular signaling and cell adhesion, and their role in cancer recurrence has been investigated. In a review of existing literature on the role of CD44/CD24 in recurrent human cancer, investigators showed positive associations between CD44+/CD24- and prognosis, especially in breast cancer; and the CD44+/CD24- phenotype of breast cancer cells was also associated with invasive properties. [5] CD44 and CD24 have been shown to regulate invasion and metastasis of breast cancer cells either positively or negatively. Tumorigenic breast cancer cells that express high levels of CD44 and low or undetectable levels of CD24 (CD44+/CD24^-/low) may be resistant to chemotherapy and therefore responsible for cancer relapse [6]. CD44 was also highly expressed in gastric adenocarcinoma and its expression correlated with poor prognosis in patients with the intestinal type of gastric adenocarcinoma [7]. Based on the implications of these previous studies, we hypothesized that CD44+/CD24- expression might be correlated with gastric cancer recurrence.

To our knowledge, current studies report no valid adhesion molecule to predict disease recurrence after patients undergo curative resection for gastric carcinoma. Because the significance of CD44+/CD24- is probably not unique to breast cancer, and CD44 has been highly expressed in gastric cancer, we might speculate that similar or other molecules may also regulate the process of recurrence for gastric cancer. Therefore, we decided to investigate the expression of adhesion molecule CD44/CD24 in recurrent gastric cancer and its possible predictive relevance in future clinical practice. The purpose of this study was to evaluate the correlation of CD44/CD24 expression with recurrent gastric cancer and to determine its prognostic significance.

Evaluation of the correlation of CD44/CD24 expression with recurrent gastric cancer revealed no differences in risk of gastric cancer recurrence between CD44+ patients and CD44- patients. Although CD24+ patients had a higher likelihood of gastric cancer recurrence than CD24- patients, significance was not demonstrated. Our study results suggest that these molecules do not appear to be clinically useful for prediction of gastric carcinoma recurrence after curative resection.

The role of CD44 and CD24 expression in gastric carcinoma has been explored for nearly thirty years. Numerous studies have focused on the diagnostic and prognostic significance of CD44 expression in human tumors, especially gastric cancer. In 1982, CD44 was identified as a surface glycoprotein and a lymphocyte homing receptor found on lymphoid and epithelial cells [8]; its main function on lymphocytes is mediating interaction with the endothelium, but its function on epithelial cells is not entirely understood [9]. The CD44 proteins belong to a family of type I transmembrane glycoproteins that are encoded by a single, highly conserved gene located on the short arm of chromosome 11 in humans; two molecular sizes have been identified: low M _r CD44 (80–90 x 10³) is expressed in lymphoid tissue and high Mr CD44 (130–160 x 10³) is expressed in tumor cells and keratinocytes [10]. Some aggressive tumors are reported to be associated with the expression of CD44. Overexpression of CD44, defined by apparently increased expression of CD44 protein, has been linked to poor prognosis with tumor progression and metastatic potential in several human malignancies, including gastric cancer [7], colorectal cancer, breast cancer [5, 6], uterine cancer, ovarian cancer, bladder cancer, lung cancer, hematopoietic malignancies, and gliomas [11]. A retrospective study of 100 patients with gastric cancer evaluated the expression of CD44 and its prognostic importance, concluding that this cell adhesion molecule is highly expressed in gastric adenocarcinoma [7]. In that study, expression of CD44 correlated with a poor prognosis in patients with the intestinal type of gastric adenocarcinoma. These investigators suggested that CD44 could be utilized as a prognostic marker for this group of patients. In this study, the proportion of lymph node metastasis was significantly higher in the GC study group than that in the control group and the proportion of patients with 5 or more metastatic lymph nodes was also significantly higher in the study group than in the control group. However, while CD44 was definitely linked with GC in our study and prognostic to some degree, we could not verify its predictive capability in terms of GC recurrence after tumor resection.

CD24, a mucin-type GPI-linked cell surface molecule on human neutrophils and pre-B lymphocytes, plays an important role in the margination and adhesion of cells under shear force of blood flow [11]. Positive CD24 expression is found to occur in a subset of GC and to correlate with lymphatic invasion, blood vessel invasion and poor survival. The clinicopathological significance of CD24 expression in human gastric adenocarcinoma was evaluated by Chou and colleagues, who concluded that cytoplasmic expression of CD24 was associated with invasiveness and poorer prognosis and can serve as a novel target for prognostic prediction and adjuvant treatment of patients with diffuse-type gastric adenocarcinoma after tumor resection [12]. Further studies are needed to investigate other combinations of adhesion molecules.

In the present study, CD44 and CD24 expression, independently and in combination, were not associated with GC recurrence. Carcinoma of the intestinal type are more frequently CD44s and CD44v6 positive than carcinomas of the diffuse type, and the importance of subclassifying tumor types in investigations of CD44 in human cancer has been demonstrated [13]. When cytoplasmic CD24 expression was studied in diffuse-type gastric adenocarcinoma, it was shown to be associated with invasiveness, lymph node metastasis and poorer prognosis, but not specifically associated with recurrence after tumor resection; however, no significant differences were seen in tumor stage or lymph node metastasis between mixed-type GC with or without CD24 expression [12]. Although there is no ideal cross-comparison between different histological grading systems, we did classify GC according to the WHO histological classification and Lauren’s classification in the present study. We had no cases of lymphoepithelial-like carcinoma or mucosa-associated lymphoid tissue (MALT) lymphoma.

Another possible explanation of lack of significant associations between CD44 and CD24 and recurrence may be the particular isoform of CD44 identified in our study. Up to seven molecular forms have varying functional roles in vivo such as having different abilities to bind hyaluronate, while their most important common feature is their expression on tumor cells and correlation with metastases [10]. These forms can be identified more readily by sequencing mRNAs and only a few are identified by protein analysis. The distribution of CD44 and CD24 may also differ and cellular sites in normal tissue have only been identified in animal models, and are not confirmed in normal human tissue. However, larger forms are found as minor components in normal tissue and low M _r forms are associated with lymphoid cell types in tissue [14]. The function of CD44/CD24 is complex and changes in CD44, in particular, have been noted in carcinogenesis, including gene expression modulation, splicing of RNA and altered glycosylation [13]. Any of the above factors may account for the apparent lack of association with recurrence in our study. Clearly, more research is needed.

Molecular pathways involved in GC have been identified over the past twenty years [15]. Current investigations of molecular markers for gastric progenitor cells and gastric stem cells may hold promise for learning more about GC, its progression and propensity for recurrence, and eventually for treatment applications. This possibility is primarily because gastric tissue, as well as intestinal tissue undergoes constant epithelial cell replacement and because stem cells and progenitor cells play important roles in the renewal of gastric glands and in epithelial repair following tissue injury [16]. Zhang et al. [17] examined CD44 and CD24 in gastric cells lines, AGS and gastric cancer tissues and identified the tumorigenic properties, self-renewal and differentiated progeny in CD44 + CD24+ and CD44-CD24- cell populations. As few as 200 of the positive combination of cells injected into mice generated tumors in 50%, while many thousands more negative combined cells were needed to form a tumor in a second group of mice, suggesting that the subpopulation of CD44 + CD24+ gastric cell lines (AGS tumor cell lines) is GC stem cells [17]. In protein studies, CD24, which is associated with tumor metastasis, and Galectin-1 expression, which is associated with immune response and tumor progression, were studied in GC patients, giving particular attention to staining intensity and clinicopathologic variables; the researchers concluded that these proteins were independent prognostic indicators of poor survival (though not specifically associated with recurrence) and could be useful as therapeutic targets [18]. Since we are not yet studying the unique progenitor and stem cell populations in human models, we should continue exploring tumor-specific protein expression that may be associated with GC and recurrent GC, seeking to find a molecular basis for this globally prevalent disease and new paths to diagnosis, prognosis and treatment.

In conclusion, neither individual expression of CD24 and CD44 nor combined expression of CD44/CD24 was associated with recurrence of gastric carcinoma. Since adhesion molecules CD44 and CD24 do not appear to be clinically useful for prediction of gastric carcinoma recurrence after curative resection, future research is warranted to both confirm these results and to investigate other possible biomarkers.